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The use of antimicrobials, primarily antibiotics, but also antivirals, antipar-
asitics, and antiseptics is rapidly rising around the world – and with it, an-
timicrobial resistance (AMR). The current COVID-19 pandemic illustrates 
both the burden on the health system and the economic costs a pathogen 
can pose when no medication is available. Concerning resistance, the crux 
of the matter lies in balancing the need to reduce overall antibiotic con-
sumption while at the same time expanding access in countries where such 
antibiotics are not easily accessible.
 • The rising use of antibiotics in health and agricultural sectors are driving the 
increase in antimicrobial resistance. The quick expansion of access and use 
along with ineffective stewardship have led to alarming resistance rates, par-
ticularly in fast-growing middle-income economies – a problem these countries 
must urgently address. 
 • If AMR is not tackled more efficiently, it is estimated that by 2050 ten million 
people will die each year from common infections that will then no longer be 
treatable. Concomitant with this will be substantial economic losses predicted 
to total 2.5 to 3 per cent of global GDP. Hence, the pressure is mounting to 
 secure more international commitment to combat AMR. 
 • Lowering antibiotic consumption might slow the pace of the spread of resistance, 
as every dose raises the risk of resistance building. Hence, the continuous develop-
ment of new medicines is crucial and requires market intervention to take place. 
 • An oft-neglected aspect of the debate over AMR is that especially in low- and 
middle-income countries many life-saving antibiotics are not or not sufficiently 
available. This situation undermines controlled distribution and promotes a 
 vicious cycle of poverty and antimicrobial resistance. 
Policy Implications
Antimicrobial resistance is a serious concern and, particularly given the pres-
ence of COVID-19, one where action should not be delayed. Policies need to ad-
dress three issues: First, emerging economies must implement effective policy 
measures to combat resistance. Second, public funding is required to remedy 
market failure. Third, international cooperation, particularly in research on di-
agnostics and prevalence as well as interventions, is necessary to better assess 
the societal impact of antimicrobial resistance and identify efficient ways to ac-
tively address the problem.
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Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, vi-
ruses, fungi, and parasites mutate such that common medicines are no longer ef-
fective to treat the infections they cause. because antibiotics, used to treat bacterial 
infections, are in wider use than antiviral drugs, we focus on antibiotic resistance 
in the following. Antibiotic resistance is a subcategory of AMR referring to bacteria 
resistant to antibiotics. These so-called “superbugs” are classified as multi-drug-
resistant (MDR) pathogens when non-susceptible to at least one agent in three or 
more antimicrobial categories, extensively drug-resistant (XDR) if bacterial isolates 
remain susceptible to only one or two categories, and pan-drug-resistant (PDR) if 
they are non-susceptible to all agents in all antimicrobial categories. The more re-
sistances, the more difficult such microorganisms are to treat and control and the 
bigger threat they pose
The Use of Antibiotics Is Rising 
Antibiotics are indispensable 
for human health. They are es-
sential for treating bacterial in-
fections and performing surgi-
cal interventions, and their use 
is increasing around the world. 
between 2000 and 2015, the 
global consumption of anti-
biotics measured in terms of 
defined daily doses (DDD) in-
creased by 65 per cent (Klein 
et al., 2018). This increase is 
largely driven by a rise in con-
sumption in emerging econo-
mies. [1] In India, at the top of the list, antibiotic consumption more than doubled in 
that 15-year period (Klein et al., 2018).
Antibiotics are used not only for human but also for animal health. Moreover, 
they also find application in food-animal production: as growth hormones and for 
sanitation purposes. Similar to the developments in human health, the consump-
tion of antibiotics is also increasing in agriculture. by 2030 the consumption of 
antibiotics in food-animal production is projected to rise by 67 per cent globally. 
Again, the driver of this escalation is an increasing consumption in fast-growing 
middle-income economies, especially brazil, Russia, India, China, and South Africa. 
Given both expected growth in the demand for livestock products and the shift to large-
scale farming in these countries, the use of antibiotic growth promoters (AGPs) is ex-
pected to double by 2030 (Van boeckel et al. 2015). Experts believe that the global 
consumption of antibiotics in animals is twice that of humans (Aarestrup, 2012).
 Current trends and projections point to a shift in antibiotic consumption from 
high-income countries to emerging economies (see Figure 1). This is consistent with 
the resistance rates we observe. In some countries in the Global South, particularly 
in Asia, resistance rates are reaching alarming levels (see Figure 2). In response to 
the growing resistance levels, the World Health Organization (WHO) has classi-
Figure 1 
Antibiotic consump-
tion in defined daily 
doses for HIC, UMIC 
and LIC/LMIC. 
Source: Klein et al., 
2018
1 In high-income coun-
tries, antibiotic consump-
tion fell by 4 per cent during 
that period (Klein et al. 
2015).
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fied 13 pathogens at risk of becoming multi-resistant. The most pressing concern 
with respect to these bacteria is the reduced effectiveness of so-called “last-line” 
 antibiotics. Although these constitute the last alternative medicines, worrying re-
sistance rates have been measured for some of them around the globe. In India 
and Nigeria, for example, resistance levels for third-generation cephalosporins and 
carbapenems – two of these last-line antibiotics – are as high as 80 per cent.
The Costs Are Considerable
Each year, 700,000 people die due to AMR, including antimalarial and antiviral re-
sistance (Review on Antimicrobial Resistance 2016). This compares to 17.8 million 
deaths due to cardiovascular diseases – the leading cause of death worldwide. If the 
current trends continue, however, deaths due to AMR could become a close second. 
by 2050 the AMR death toll is expected to reach ten million a year (Review on An-
timicrobial Resistance 2016). The largest burden will be in the Global South: of all 
AMR-related deaths, 90 per cent are expected to occur in Africa and Asia (Review 
on Antimicrobial Resistance 2016).  
In addition to the loss of human lives, the economic costs will also be substan-
tial. The estimated magnitudes are in the range of 2.5 to 3 per cent of the world’s 
GDP. This is equivalent to a loss of uSD 100 trillion by 2050 (Review on Antimi-
crobial Resistance 2016). These estimates are similar to the costs associated with a 
2°C rise in global average surface temperature (Roope et al. 2019). Yet, these num-
bers have to be taken with a pinch of salt. The economic costs of AMR are fraught 
with uncertainty and a lack of reliable data, maybe even more so than the estimates 
for climate change. For many countries, reliable information on resistance levels is 
lacking (see Figure 1); for those countries in the Global South for which we do have 
data, rates are often based on lower-frequency, highly selected samples and thus 
estimated with a large margin of error. 
Fighting AMR
Tackling AMR requires ending overuse of antibiotics. but what is the alternative? 
High-income countries use a system of controlled distribution, with physicians 
prescribing and pharmacies selling antibiotics. In emerging and even more so in 
Figure 2 
Antimicrobial Resist-
ance Rates around the 
World 
Source: L. Roope et al. 
2019.
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low- and middle-income countries (LMIC), consumption is greatly influenced by 
unregulated supply chains and by purchase without prescriptions over the counter 
(OTC). A systematic review by Sakeena et al. (2018) shows that in LMICs 60 per 
cent of antibiotics are sold OTC without prescription. The resulting self-medicating 
represents a major problem in LMICs, one that has been largely neglected. While 
making prescriptions mandatory may solve the problem, it might not be enough. 
In high-income countries, where OTC sales are more regulated, rates of erroneous 
or inadequate prescriptions by doctors are extremely high. Recent estimations in-
dicate that approximately one-third of antibiotic prescriptions in the united States 
were unnecessary. For the United Kingdom, the numbers are even higher: experts 
found that over 80 per cent of the prescriptions there were unnecessary (Fleming-
Dutra et al. 2016; Pouwels et al. 2018). 
What we need is a more in-depth understanding of how antibiotics are pre-
scribed and consumed. Sensitising and incentivising health professionals and the 
public vis-à-vis when and how to use antibiotics (e.g. not to self-medicate, and to 
adhere to the treatment schedule) could discourage improper use. Yet, thus far, we 
have little systematic evidence on how overcoming information constraints actually 
affects antibiotic use. From other information interventions on sensitising health 
professionals or patients to drug use, treatment, and preventive measures in health, 
which have mostly focused on the short term, we can only conclude that effects are 
mixed and very context-specific. 
Over-prescription could also be reduced by access to better diagnostics. This is-
sue is particularly relevant in resource-poor settings, which lack clinical diagnostics 
for accurate treatment. In contexts with a high burden of diseases, health practi-
tioners often prescribe more aggressive antibiotics than are actually needed, to be 
on the “safe” side. In Malawi, for example, health practitioners are encouraged to 
treat all patients with fever with antibiotics or write prescriptions based on avail-
ability rather than suitability – practices that inevitably result in over-prescription. 
In consequence, reducing antibiotic use to socially desirable levels will require 
better tools and information, a better understanding of the incentives of consump-
tion, and better monitoring and stewardship. This applies not only to health but 
also to agriculture. Stricter regulation of AGPs is a step in the right direction. The 
European union’s tightened restrictions on prophylactic antibiotics have proven 
fruitful; to take one example, the quantity of veterinary antibiotics sold in Germany 
dropped 57 per cent between 2011 and 2017 (German Federal Ministry of Health 
2019). by contrast, brazil is the only emerging economy with at least a partial ban 
on AGPs. 
Reductions in the use of antibiotics, however, will only slow the pace at which 
resistances generate: susceptibility to current antibiotics will continue to decrease. 
Hence, it is vital to develop new, effective antibiotics. Of course, such development 
is costly, and if left to the market, it is unlikely that we will see timely progress. 
Most of the major pharmaceutical companies – 21 of the top 25 companies – have 
stopped research and development (R&D) on antibiotics. Since antibiotics should 
be used scarcely in order to keep resistances at bay, the development of new antibi-
otics is not lucrative – a classic case of market failure. 
Research on new antibiotics is now mostly in the hands of start-ups and small 
and medium enterprises (SMEs), which lack the financial capacity to push their 
products through the evaluation processes necessary for market authorisation. The 
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most challenging part – called “the valley of death” – is to pass from the preclini-
cal (animal testing) to the clinical (human testing) development stage. After that, 
the financial hurdle is still not easy to overcome: 80 per cent of the costs for new 
antibiotics are spent on the operational costs of moving an antibiotic from phase 
one to phase three of clinical trials, an amount estimated to be upwards of uSD 130 
million (Review on Antimicrobial Resistance 2016). Taking into account that only 
14 per cent of drugs enrolled in clinical development reach the market, the risk for 
developers is high (Wong et al. 2019). 
To date there are 138 antibiotics-related projects in the pipeline (Antimicrobial 
Resistance Access to Medicines Foundation Report 2020). That might sound like a 
lot, but to put it into perspective there are more than 800 projects in  oncology. Fur-
thermore, since 1990, no novel classes of antibiotics with distinct chemical struc-
tures have reached the market. In light of the reduced research activities and the 
high financial costs, if and when new antibiotics reach the market remains an open 
question. 
The market alone will thus not generate a sufficient number of new antibiotics, 
so innovative approaches must be taken to overcome the market failure and incen-
tivise R&D in new antibiotics. Three options are plausible: 
1. Using public funds to financially reward development, similar to the approach 
successfully used by the Drugs for Neglected Diseases initiative (DNDi). Re-
ward-based incentives financed by a global fund would not only increase the 
quantity of R&D projects but also allow the direction of research to be de-
termined by something other than sales figures. This approach has also been 
proven effective by the Global Fund to Fight AIDS, Tuberculosis and Malaria. 
Rewards would need to constitute about USD 1.6 billion per year to effectively 
“de-link” profitability from sales volume. This is about three times the amount 
currently spent by the public sector worldwide to promote AMR-relevant re-
search. Hence, more resources would need to be redirected – something un-
likely to happen in the short run.
2. Extending patent protections. For example, the uS Food and Drug Administra-
tion (FDA) confers market exclusivity for the development of drugs targeting 
rare diseases, during which time no generics can be approved. 
3. Establishing a “fast-track” approval process combined with a tradeable  voucher, 
similar to the one created by the FDA to tackle tropical and rare paediatric dis-
eases. Such a programme would provide companies a tradeable voucher that 
allows the corporation to have any one of their drugs evaluated more quickly. 
The Real Problem Might Be Access Not Excess
While there is increasing recognition that antimicrobial resistance is a serious 
public health problem, one important issue has been overlooked. Currently, more 
 people die from a lack of access to antibiotics than from resistant bacterial patho-
gens. The estimated 700,000 deaths from antibiotic-resistant infections are sub-
stantially outnumbered by the 5.7 million deaths each year – most occurring in 
LMICs – that could be prevented by antibiotics. 
Thus far, the lack of access to antibiotics has received comparably little at-
tention. Reasons for lack of access are poorly understood, and potential solutions 
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have gone largely unexplored. The problem is often reduced to one of financial con-
straints. Despite an increasing push for universal health insurance in LMICs, out-
of-pocket expenditures for health are still high, with households spending between 
25 and 70 per cent of their income on health care and medicines. because of the 
high costs, patients often buy incomplete courses, which in turn could both lead to 
treatment failure and promote resistance, creating a vicious cycle. As bacteria are 
becoming resistant to first-line antibiotics, there is a need for second- and third-line 
antibiotics, which are more expensive. In some countries, second- and third-line 
antibiotics can cost up to 60 times the price of first-line medicines, even when all of 
the latter are generic. Higher costs for the treatment of resistant bacteria are put-
ting people at risk of slipping into poverty. Studies estimate that 28.3 million people 
could fall into extreme poverty by 2030 because of antimicrobial resistance (Ahmed 
et al. 2018). Yet, we have insufficient empirical evidence on which groups are most 
affected by the lack of access, how access varies by income level, or the implications 
of these patterns. This is an important factor to consider when discussing policy 
interventions (subsidies being just one example) to overcome the access problem. 
The access problem, however, has several layers. It is not only one of not be-
ing able to afford medicines, but also one of poor-quality medicines circulating in 
the market. Of the substandard or falsified medicines reported to the WHO, 17 per 
cent are antibiotics. Substandard antibiotics cause 169,000 childhood pneumonia 
deaths each year. Yet, the problem goes even further. Similar to pursuing R&D for 
new antibiotics, producing antibiotics is also becoming less and less interesting 
for pharmaceutical companies. This has implications for entire supply chains and 
will aggravate the provisioning of antibiotics in LMICs. Currently, manufacturers 
already supply only 14 out of 30 established antibiotics to LMICs (Antimicrobial 
Resistance Acces to Medicines Foundation Report, 2020). For novel antibiotics, the 
picture is even bleaker: according to the 2020 Antimicrobial Resistance Benchmark 
Report, only three of the 13 patented novel antibiotics are available in more than 
ten of the LMICs. 
 Walking the Line: Expanding Access without Generating Excess
It is evident that we must reduce excess use of antibiotics. Yet, it is also critical to 
remember that in low- and middle-income countries the still bigger problem is one 
of access rather than overconsumption. Increasing access to antibiotics is essential 
to reducing the infectious disease burden in LMICs. However, expanding access 
without stewardship and regulation is dangerous. The fast-growing middle-income 
countries are a case in point. Without sufficient controls, resistance rates can quickly 
rise to alarming rates, as we have seen in India and Nigeria.  
Diseases and bacteria travel beyond traditional borders – the current COVID-19 
pandemic illustrates that pertinently. The COVID-19 pandemic has also shown that 
in times of crisis, countries resort to national measures, even though a coordinated, 
international approach might be more efficient in controlling and overcoming the 
crisis; in light of the steep initial development of the crisis, a coordinated response 
seemed out of reach. Though, like COVID-19, AMR does not respect borders, it is 
nevertheless a predictable threat. Resistances spread as fast as their carriers do. 
Whether viruses, bacteria, or other microorganisms, they all use waterways, food 
chains, or humans to jump onto their next host. Intertwined travelling networks 
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and international supply chains make it easy for pathogens to travel across the 
globe. To date [27.03.2020], uSD 7 trillion  has been spent worldwide to stop the 
spread of COVID-19 (Horowitz 2020). This shows the potential of governments to 
respond with vast sums of money in a short period of time to counteract an acute 
global threat. Antibiotic resistance is not yet classified as an acute crisis for which 
short-term measures need to be taken. Rather, we are at a point where structural 
and longer-term actions should be taken to address the threat of antimicrobial re-
sistance more cost-effectively and sustainably. 
Improving access needs to be at the fore. Addressing infections treatable with 
antibiotics “at home” will eventually help prevent the rise of superbugs. If resist-
ance renders treatments ineffective, efforts to improve access to antibiotics will be 
futile, with global consequences. Antibiotic stewardship and infection prevention 
must, therefore, be pursued alongside improvements in access. balancing access 
and excess requires the engagement of all players in the health system along with 
holistic interventions to educate consumers, incentivise the pharmaceutical sector, 
and promote access to effective antibiotics globally. Small efforts are being made 
in this direction. The Global Antibiotic Research and Development Partnership 
(GARDP) – an international non-profit organisation – is working to ensure sus-
tainable access to newly produced antibiotics. More recently, the FDA, the Euro-
pean Medicines Agency, and the Japanese Pharmaceuticals and Medical Devices 
Agency joined together to reduce the requirements for clinical data on drugs for 
infections with limited treatment options to speed up the time to market. However, 
the focus should be on low- and middle-income countries, which receive vaccines 
and medicines four to seven years after high-income countries have access to them 
(Ahonkhai et al. 2016). Supply chains are still insufficiently expanded, and incon-
sistent regulatory standards represent real barriers in LMICs. Organisations such as 
the African Medicines Regulatory Harmonization (AMRH) initiative, which attempts 
to improve medicine registration in Africa through cost-effective use of the limited 
financial, technical, and human resources available, are a step in the right direction.
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